Fulltext

Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?

Bonnefoi, H. ; Diebold-Berger, S. ; Therasse, P. ; Hamilton, A. ; van de Vijver, M. ; MacGrogan, G. ; Shepherd, L. ; Amaral, N. ; Duval, C. ; Drijkoningen, R. ; Larsimont, D. ; Piccart, M.

In: Annals of Oncology, 2003, vol. 14, no. 3, p. 406-413

Ajouter à la liste personnelle
    Titre
    • Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?
    Auteur
    • Bonnefoi, H.. Hôpitaux Universitaires de Genève, Geneva, Switzerland
    • Diebold-Berger, S.. Hôpitaux Universitaires de Genève, Geneva, Switzerland
    • Therasse, P.. EORTC Data Center, Brussels
    • Hamilton, A.. Institut J. Bordet, Brussels, Belgium
    • van de Vijver, M.. Netherlands Cancer Institute, Amsterdam, The Netherlands
    • MacGrogan, G.. Institut Bergonié, Bordeaux, France
    • Shepherd, L.. NCIC Clinical Trials Group, Kingston, Canada
    • Amaral, N.. Hospitais da Universidade, Coimbra, Portugal
    • Duval, C.. Centre Henri Becquerel, Rouen, France
    • Drijkoningen, R.. University Hospital, Leuven, Belgium
    • Larsimont, D.. Institut J. Bordet, Brussels, Belgium
    • Piccart, M.. Institut J. Bordet, Brussels, Belgium
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Annals of Oncology, 2003, vol. 14, no. 3, p. 406-413. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:291763
    Summary
    Background: Locally advanced and/or inflammatory breast cancer (LABC) is a heterogeneous disease. Molecular markers may help to understand this heterogeneity. This paper reports the results of a study assessing the potential prognostic or predictive value of HER-2, p53, cyclinD1, MIB1, ER and PgR expression by immunohistochemistry from patients included in an EORTC-NCIC-SAKK trial. Patients and methods: A total of 448 patients with a cytological or histological diagnosis of LABC were randomised into a trial comparing two anthracycline-based neoadjuvant regimens. Chemotherapy was followed by standard locoregional therapy. Survival was comparable in both arms. We collected and analysed centrally paraffin-embedded tumour specimens from 187 (72.5%) of 258 patients that had a histological diagnosis. Results: Of the patients included in this molecular marker study 114 relapsed and 91 died. In the multivariate analysis p53 positivity was associated with a shorter progression-free survival [hazard ratio (HR) = 1.96; 95% CI 1.33-2.91; P = 0.0008) and a shorter overall survival (HR = 1.98; 95% CI 1.28-3.06; P = 0.002). PgR positivity predicted for a longer overall survival (HR = 0.54; 95% CI 0.35-0.83; P = 0.0045). Conclusions: p53 was an independent factor predicting for survival. In order to clarify whether p53 is a pure prognostic and/or a predictive factor, a phase III trial is being conducted (EORTC 10994/BIG 00-01 study) using functional assay in yeast from frozen tumour samples